Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells

Cell Cycle

Volumn 12, Issue 22, 2013, Pages 3471-3477

  Vazquez Martin, Alejandro ^a,b   Cufí, Sílvia ^a,b   Lopez Bonet, Eugeni ^c   Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   Vellon, Luciano ^d   Iglesias, Juan Manuel ^e   Leis, Olatz ^f   Martín, Ángel G ^f   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d Fundacion Inbiomed   (Spain)

^e Biomedical Research and Technological Development Institute   (Spain)

^f StemTek Therapeutics   (Spain)

Author keywords

Breast cancer; Cancer stem cells; Estradiol; Estrogen receptor; SOX2

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; MATRIGEL; TAMOXIFEN; TRANSCRIPTION FACTOR SOX2;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL STRAIN MCF 7; CELL SURVIVAL; METAPHASE; NONHUMAN; NUCLEAR REPROGRAMMING; PROMETAPHASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION;

BREAST CANCER; CANCER STEM CELLS; ESTRADIOL; ESTROGEN RECEPTOR; SOX2;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING; PHOSPHORYLATION; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS;

EID: 84890346903     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26692     Document Type: Article

References (23)

1. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A.mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi.org/10.4161/cc. 10.21.18128
2. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, Martin AG, Martin-Castillo B, López-Otín C, Menendez JA.Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.Cell Cycle 2012; 11:974-89; PMID:22333578; http://dx.doi.org/10.4161/ cc.11.5.19450
3. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A.The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Cell Cycle 2013; 12:1166- 79; PMID:23549172; http://dx.doi.org/10.4161/ cc.24479
4. Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T, Vellon L, Iglesias JM, Leis O, et al.Nuclear reprogramming of luminal-like breast cancer cells generates Sox2- overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Cell Cycle 2013; 12:3109-24; PMID:23974095;
5. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, et al.The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer.J Biol Chem 2008; 283:17969-78; PMID:18456656;
6. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG.Sox2 expression in breast tumours and activation in breast cancer stem cells.Oncogene 2012; 31:1354-65; PMID:21822303;
7. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, Müller F, Schneider F, Petersen K, Wallwiener D, Kanz L, et al.Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma.BMC Cancer 2011; 11:42; PMID:21276239; http://dx.doi.org/10.1186/1471-2407-11-42
8. Enver T, Pera M, Peterson C, Andrews PW.Stem cell states, fates, and the rules of attraction.Cell Stem Cell 2009; 4:387-97; PMID:19427289; http:// dx.doi.org/10.1016/j.stem.2009.04.011
9. Abollo-Jiménez F, Jiménez R, Cobaleda C.Physiological cellular reprogramming and cancer.Semin Cancer Biol 2010; 20:98-106; PMID:20188173;
10. Vicente-Dueñas C, Romero-Camarero I, Cobaleda C, Sánchez-García I.Function of oncogenes in cancer development: a changing paradigm.EMBO J 2013; 32:1502-13; PMID:23632857; http://dx.doi.org/10. 1038/emboj.2013.97
11. Dontu G, El-Ashry D, Wicha MS.Breast cancer, stem/progenitor cells and the estrogen receptor.Trends Endocrinol Metab 2004; 15:193-7; PMID:15223047; (Pubitemid 38833988)
12. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, Kuperwasser C.Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.Proc Natl Acad Sci U S A 2010; 107:21737-42; PMID:21098263; http:// dx.doi.org/10.1073/pnas.1007863107
13. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS.Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression.PLoS One 2011; 6:e28068; PMID:22132214; http://dx.doi.org/10.1371/journal.pone.0028068
14. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER.Integration of the non-genomic and genomic actions of estrogen.Membrane-initiated signaling by steroid to transcription and cell biology.J Biol Chem 2002; 277:50768-75; PMID:12372818; (Pubitemid 36042240)
15. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.J Natl Cancer Inst 2004; 96:926-35; PMID:15199112; (Pubitemid 38868139)
16. Osborne CK, Shou J, Massarweh S, Schiff R.Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.Clin Cancer Res 2005; 11:865s-70s; PMID:15701879 (Pubitemid 40111098)
17. Massarweh S, Schiff R.Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.Clin Cancer Res 2007; 13:1950-4; PMID:17404074; (Pubitemid 46649859)
18. Arpino G, Wiechmann L, Osborne CK, Schiff R.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.Endocr Rev 2008; 29:217- 33; PMID:18216219; http://dx.doi.org/10.1210/ er.2006-0045 (Pubitemid 351519691)
19. Sudhagar S, Sathya S, Lakshmi BS.Rapid nongenomic signalling by 17?-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells.Br J Cancer 2011; 105:953- 60; PMID:21897387; http://dx.doi.org/10.1038/ bjc.2011.349
20. Zhang Y, Eades G, Yao Y, Li Q, Zhou Q.Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2.J Biol Chem 2012; 287:41514-22; PMID:23060440; http://dx.doi.org/10.1074/jbc.M112.404871
21. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras- Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA.Metformin: multi-faceted protection against cancer.Oncotarget 2011; 2:896-917; PMID:22203527
22. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA.Metformininduced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.Oncotarget 2012; 3:395-8; PMID:22565037
23. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P.Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.Nucleic Acids Res 2012; 40:6725- 40; PMID:22561374; http://dx.doi.org/10.1093/ nar/gks360.